📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. (2013)

First Author: HPS2-THRIVE Collaborative Group

Attributed to: CTSU resubmission: Proposal to increase capacity for methodological improvements in clinical trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/eurheartj/eht055

PubMed Identifier: 23444397

Publication URI: http://europepmc.org/abstract/MED/23444397

Type: Journal Article/Review

Volume: 34

Parent Publication: European heart journal

Issue: 17

ISSN: 0195-668X